Azucena Salas

A new study from Shaare Zedek Medical Center demonstrates the potential for a whole-food diet called Tasty&Healthy™, in managing Crohn’s disease. The research found that this approach can induce remission in children and young adults with mild to moderate Crohn’s and was better tolerated than exclusive enteral nutrition. This approach marks an important step toward sustainable, everyday treatments for inflammatory bowel disease. Read this Helmsley-supported study at Gastroenterology: bit.ly/3Lyi3xy

🚨 Last chance! Join the IFCCA Academy’s 2nd online module with FIBROTARGET: 🎥 Living with Fibrosis: Challenges, Treatments & Innovations Learn about the latest in intestinal fibrosis with expert & patient insights. ⏰ Register by 3 Nov: lnkd.in/ebXVwYpR

⭐ Please consider joining our Single Cell Genomics group as Computational PhD Student! ♦️ We are hiring 2 Computational Biology PhD students to lead projects in immuno-oncology (IO) and immune-mediated inflammatory diseases (IMID), respectively. In #IO, we aim to delineate mechanisms and dynamics of immune cell infiltration and plasticity in tumors, to provide precise prediction of therapy success. In #IMID, we seek to identify inflammatory disease-specific biomarkers to understand mechanisms driving disease progression and response to treatment across large acute and chronic patient cohorts. While applying single-cell and spatial genomics tools to delineate the complexity of tumors or inflamed tissues, a particular focus lies on the use of blood samples as a liquid biopsy tool for repeated, longitudinal studies. This will allow us to build predictive models for patient outcome and, eventually, foundation models for immune cell plasticity and natural/clinical perturbations. Apply here: 👇 cnag.eu/jobs/phd-stude…

Best part of being in projects like this is working with young talented researchers like Gaia👩🏻‍🔬🔬!

This is so cool!

Patients from our unit visited our lb to learn about our research! It was a priviledge for the entire team🙌🏻 thanks🫶🏻

@RBartolom, @AzucenaSalas17 and I have joined forces to gather the current scRNA-seq and/or ST studies in #IBD. From validating previous findings to identifying new cell types... these technologies are really revolutionising the field! Check out our review in #gut for more :)

FIBROTARGET aims to change the status quo in #IBD research with novel therapeutics for fibrosis. We spoke with one of FIBROTARGET's researchers Victoria Gudiño from @idibaps (@hospitalclinic) about her role and its impact. 🗞️ Read the full interview: loom.ly/tQKNvNI

We believe that the most effective way to help individuals at risk of developing Crohn’s disease is to prevent the condition from developing in the first place or to delay disease progression for as long as possible. Our Prevention focus area supports projects aimed at improving our understanding of the disease course. This includes uncovering the root causes, studying geographical trends as incidences of the disease continue to rise, and exploring the role of diet in both disease onset and progression. The Prediction and Prevention through Omics, Microbiome, Immune System, and Environment (PROMISE) Consortium at @IcahnMountSinai is focused on assessing Crohn’s disease-associated biomarkers in populations at high risk for developing the condition, but before diagnosis. Researchers are investigating whether these biomarkers can predict disease progression and identify the key drivers of disease development. This data is critical to expanding our understanding of early disease onset, and it will help inform future treatment and prevention therapies. Read about our Prevention focus area: bit.ly/3ZBN7RV #CrohnsDisease #CCAwarenessWeek #IBD

Nuestro grupo @ibd_bcn en las noticias 🔬🧬#ibd #scRNA elpais.com/ciencia/2024-1…

🔬 Basic scientists, submit your translational research to @UEGJournal and make a difference in patient care. With #UEGJ, you'll have access to a global community of digestive health experts to review and publish your work. bit.ly/3OoWizy #weareUEG #myUEGcommunity

Proud of our team's contribution to this amazing effort led by @teichlab nature.com/articles/s4158…

We are thrilled to share an HCA Collection of 40+ peer-reviewed papers in @NaturePortfolio shedding light on human development, healthy and disease biology and vital analytical tools. #HCA2024NatureCollection #HumanCellAtlas nature.com/immersive/d428…

📌 'La Vanguardia' deja de publicar tuits de forma directa en la red social X, convertida en una red de desinformación desde la llegada de Musk #Echobox=1731565211" target="_blank" rel="nofollow noopener">lavanguardia.com/vida/20241114/…

Bluesky adds 700,000 new members as users flee X after the US election dlvr.it/TG7Jtl

Why the Guardian is no longer posting on X theguardian.com/media/2024/nov…

With the right people, right funding, and right opportunity, we at @fibrotarget are creating the momentum needed to turn possibilities into breakthroughs in research 🔬 . More about Dr. @SeverineVermei1 and her contributions to the field here ⤵️ ibd-leuven.com/medical-staff-…

Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at gmagri@ub.edu.

🎙️ Mecanismos patogénicos en enfermedades inmunomediadas: ¿vías orgánicas vs comunes? 👥Únete a los expertos para conocer los mecanismos patogénicos de la inflamación y el daño orgánico, centrados en órganos y sistemas Regístrate👇 aulaclinic.com/cursos/view.ph…

What happens to intestinal cells when patients are treated with tofacitinib? Why do responses vary between patients? Check out a new preprint from our lab for some responses @ibd_bcn @ibdleuven #IBD #scRNAseq biorxiv.org/content/10.110…